Kaplan HSB. Concise textbook of clinical psychiatry. William & Wilkins: Baltimore; 1996.
Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9:808–16. 818–821.
Keller MBLP, Mueller TI. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49:809–16.
Olfson M, Marcus S, Sackeim HA, Thompson J, Pincus HA. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry. 1998;155:22–9.
George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry. 2013;26:13–8.
Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015;14:64–73.
Kozel FAGM, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr. 2004;9:476–82.
Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007;68:711–20.
Hundt NE, Barrera TL, Robinson A, Cully JA. A systematic review of cognitive behavioral therapy for depression in Veterans. Mil Med. 2014;179:942–9.
Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160:3252–7.
Sackeim HAPJ, Devanand DP. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10:96–104.
Rossi S, Hallett M, Rossini PM, Pascual-Leone A, Safety of TMSCG. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120:2008–39.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–77.
Beck AT, Steer RA, Ranieri WF. Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44:499–505.
Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol. 1974;42:861–5.
Spielberger CD, Sydeman SJ. State-Trait Anxiety Inventory and State-Trait Anger Expression Inventory. In: The use of psychological testing for treatment planning and outcome assessment. Hillsdale, NJ, England: Lawrence Erlbaum Associates, Inc; 1994. p. 292–321.
Selzer ML. Michigan Alcoholism Screening Test (MAST): preliminary report. Univ Mich Med Cent J. 1968;34:143–5.
Skinner HA. The drug abuse screening test. Addict Behav. 1982;7:363–71.
Sobell LC, Agrawal S, Annis H, Ayala-Velazquez H, Echeverria L, Leo GI, Rybakowski JK, Sandahl C, Saunders B, Thomas S, Zioikowski M. Cross-cultural evaluation of two drinking assessment instruments: alcohol timeline followback and inventory of drinking situations. Subst Use Misuse. 2001;36:313–31.
George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995;6:1853–6.
George MS, Wassermann EM, Williams WA, Steppel J, PascualLeone A, Basser P, Hallett M, Post RM. Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. J Neuropsychiatry Clin Neurosci. 1996;8:172–80.
Herwig U, Satrapi P, Schonfeldt-Lecuona C. Using the International 10-20 EEG system for positioning of transcranial magnetic stimulation. Brain Topogr. 2003;16:95–9.
Herbsman T, Avery D, Ramsey D, Holtzheimer P, Wadjik C, Hardaway F, Haynor D, George MS, Nahas Z. More lateral and anterior prefrontal coil location is associated with better repetitive transcranial magnetic stimulation antidepressant response. Biol Psychiatry. 2009;66:509–15.
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67:507–16.
Johnson KA, Baig M, Ramsey D, Lisanby SH, Avery D, McDonald WM, Li XB, Bernhardt ER, Haynor DR, Holtzheimer PE, et al. Prefrontal rTMS for treating depression: location and intensity results from the OPT-TMS multi-site clinical trial. Brain Stimul. 2013;6:108–17.
Nahas Z, Li XB, Kozel FA, Mirzki D, Memon M, Miller K, Yamanaka K, Anderson B, Chae JH, Bohning DE, et al. Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study. Depress Anxiety. 2004;19:249–56.
Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012;72:595–603.
Brown GG, Mathalon DH, Stern H, Ford J, Mueller B, Greve DN, McCarthy G, Voyvodic J, Glover G, Diaz M, et al. Multisite reliability of cognitive BOLD data. Neuroimage. 2011;54:2163–75.
Douglas KP, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Aust NS J Psychiatry. 2009;43:1105–17.
Serafini GP, Pompili M, Belvederi Murri M, Respino M, Ghio L, Girardi P, Fitzgerald PB, Amore M. The effects of rTMS on cognitive performance in TRD. A systematic review. Neuropsychobiology. 2015;71:125–39.
Gold MR SJ, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
Ramsey SWR, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force Report. Value Health. 2005;8:521–33.
Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33:344–9.
Micallef-Trigona B. Comparing the effects of rTMS and ECT in the treatment of depression: a systematic review and meta-analysis. Depress Res Treat. 2014;2014:1155.
Keszior K, Azorina V, Reitz SK. More female patients and fewer stimuli per session are associated with short-term antidepressant properties of rTMS: a meta-analysis of 54 sham-controlled studies published between 1997 and 2013. Neuropsychiatr Dis Treat. 2014;10:727–56.
Grammer G, Kuhle AR, Clark CC, Dretsch MN, Williams KA, Cole JT. Severity of depression predicts remission rate using TMS. Front Psychiatry. 2015;6:114.
Grunhaus L, Dannon PN, Schreiber S. rTMS is as effective as ECT in the treatment of nondelusional major depression: an open study. Biol Psychiatry. 2000;47:314–24.
Cheeran B, Talelli P, Mori F, Koch G, Suppa A, Edwards M, Houlden H, Bhatia K, Greenwood R, Rothwell JC. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol. 2008;586:5717–25.
Pena-Gomez C, Sole-Padulles C, Clemente IC, Junque C, Bargallo N, Bosch B, Molinuevo JL, Valls-Sole J, Pascual-Leone A, Bartres-Faz D. APOE status modulates the changes in network connectivity induced by brain stimulation in non-demented elders. PLoS One. 2012;7:e51833.
Bocchio-Chiavetto L, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C, Gennarelli M. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett. 2008;437:130–4.